

PUBLICATIONS: JOURNAL ARTICLES

1. Feferman I. and Snow A.D. Pica: A review. Modern Medicine of Canada. 36:441-443, 1981.
2. Snow A.D. and Altmann G.G. Time-related increase of nucleolar size and villus cell number during DMH carcinogenesis in the rat duodenal epithelium. Cell Biology International Reports 7: 195, 1983.
3. Snow A.D. and Altmann G.G. Morphometric study of the rat duodenal epithelium during the initial six months of 1,2-dimethylhydrazine treatment. Cancer Research 43:4838-4849, 1983.
4. Altmann G.G. and Snow A.D. Effects of 1,2-dimethylhydrazine on the number of epithelial cells present in the villi, crypts and mitotic pool along the rat small intestine. Cancer Research 44: 5522-5531, 1984.
5. Kisilevsky R., Tan R., Subrahmanyam L. and Snow A.D. Are elevated serum amyloid A levels and amyloid enhancing factor sufficient to induce AA amyloid deposition? Applied Pathology 2: 308-315, 1984.
6. Snow A.D. and Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Laboratory Investigation 53: 37-44, 1985.
7. Snow A.D., Willmer J. and Kisilevsky R. Sulfated glycosaminoglycans: A common constituent of all amyloids? Laboratory Investigation 56:120-123, 1987.
8. Snow A.D., Willmer J. and Kisilevsky R. Sulphated glycosaminoglycans in Alzheimer's disease. Human Pathology 18: 506-510, 1987.
9. Snow A.D., Kisilevsky R., Stephens C. and Anastassiades T. Characterization of plasma and tissue glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis. Laboratory Investigation 56: 665-675, 1987.
10. Snow A.D., Kisilevsky R., Stephens C. and Anastassiades T. Electrophoresis of glycosaminoglycans isolated from normal human plasma. Direct evidence for the presence of a heparin-like molecule. Biomedica Biochimica Acta 46: 537-547, 1987.
11. Snow A.D., Kisilevsky R. and Willmer J. A close ultrastructural relationship between sulphated proteoglycans and AA amyloid fibrils. Laboratory Investigation 57: 687-698, 1987.
12. Kisilevsky R. and Snow A.D. The potential significance of sulphated glycosaminoglycans as a common constituent of all amyloids; or perhaps amyloid is not a misnomer. Medical Hypotheses 26:231-236, 1988.
13. Snow A.D., Mar H., Nochlin D., Kimata K., Kato M., Suzuki S., Hassell J. and Wight T.N. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. American Journal of Pathology 133:456-463, 1988.
14. Snow A.D., Kisilevsky R., Willmer J., Prusiner S.B. and DeArmond S.J. Sulphated glycosaminoglycans in amyloid plaques in prion diseases. Acta Neuropath 77:337-342, 1989.

15. Nochlin D., Sumi S.M., Bird T.D., Snow A.D., Masters C.L. and Beyreuther, K. Familial dementia with PrP positive amyloid plaques. A variant of Gerstmann-Straussler syndrome. *Neurology* 39:910-918, 1989.
16. Snow A.D., Lara S., Nochlin D. and Wight T.N. Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. *Acta Neuropathologica* 78:113-123, 1989.
17. Snow A.D. and Wight T.N. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. *Neurobiology of Aging* 10:481-497, 1989.
18. Snow A.D. and Wight T.N. Author's response to commentaries. *Neurobiology of Aging* 10:510-512, 1989.
19. Snow A.D., Bolender R.P., Wight T.N. and Clowes A.W. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. *American Journal of Pathology* 137:313-330, 1990.
20. Snow A.D., Wight T.N., Nochlin D., Koike Y., Kimata K., DeArmond S.J. and Prusiner, S.B. Immunolocalization of heparan sulfate proteoglycans to prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. *Laboratory Investigation* 63:601-611, 1990.
21. Snow A.D., Mar H., Nochlin D., Sekiguchi R.T., Kimata K., Koike Y. and Wight T.N. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein containing lesions of Alzheimer's disease and Down's syndrome. *American Journal of Pathology* 137:1253-1270, 1990.
22. Snow A.D., Wight T.N., Mar H., Bramson R. and Kisilevsky R. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. *J Histochem Cytochem* 39:1321-1330, 1991.
23. Snow A.D., Mar H., Nochlin D., Kresse H. and Wight T.N. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. *J Histochem Cytochem* 40:105-113, 1992.
24. Fukuchi K., Deeb, S.S., Kamino K., Ogburn C.E., Snow A.D., Sekiguchi R.T., Wight T.N., Piusson H. and Martin G.M. Increased expression of beta-amyloid protein precursor and microtubule-associated protein tau during the differentiation of murine embryonal carcinoma cells. *J of Neurochem* 58:1863-1873, 1992.
25. Snow A.D. and Malouf A. In vivo and in vitro models to unravel the role of β /A4 in the pathogenesis of Alzheimer's Disease. *Hippocampus* 3:257-267, 1993.
26. Crutcher K.A., Anderton B., Barger S., Ohm T., and Snow A.D. Mechanisms of cellular and molecular pathology of Alzheimer's Disease. *Hippocampus* 3:271-288, 1993.
27. Snow A.D., Sekiguchi R., Nochlin D., Fraser P., Kimata K., Mitzutani A., Arai M., Schreier W.A. and Morgan D.G. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar A β amyloid in rat brain. *Neuron* 12: 219-234, 1994.

28. Snow A.D., Sekiguchi R., Nochlin D., Kalaria R.N. and Kimata K. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not in cerebellum of Alzheimer's disease brain. *American Journal of Pathology* 144:337-347, 1994.
29. Jucker M., Walker L.C., Schwarb P., Hengemihle J., Kuo H., Snow A.D., Bamert F. and Ingram D.K. Age-related deposition of glia-associated fibrillar material in brains of C57BL/6 mice. *Neuroscience* 60:875-889, 1994.
30. Sekiguchi R.T., Potter-Perigo S., Braun K., Miller J., Ngo C., Fukuchi, K., Wight T.N, Kimata, K. and Snow A.D. Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation. *J Neuroscience Research*, 38:670-686, 1994.
31. Fraser P.E., McLachlan D.R., Surewicz W.T., Mizzen C.A., Snow A.D., Nguyen J.T., and Kirschner D.A. Conformation and fibrillogenesis of Alzheimer A β peptides with selected substitutions of charged residues. *J. Molecular Biology* 244:64-73, 1994.
32. Snow A.D., Kinsella M.G., Parks E., Sekiguchi R.T., Miller J.D., Kimata K., and Wight T.N. Differential binding of vascular cell derived proteoglycans (perlecan, biglycan, decorin and versican) to the beta-amyloid protein of Alzheimer's disease. *Arch. Biochemistry Biophysics* 320:84-95, 1995.
33. Snow A.D., Nochlin D., Sekiguchi R., and Carlson S. Identification and immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's Disease. *Experimental Neurology* 138:305-317, 1996.
34. Castillo G.M., Cummings J.A., Ngo C., Yang W., and Snow A.D. Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A β amyloid persistence in brain. *Journal of Biochemistry* 120:433-444, 1996.
35. Maresh G.A., Erezylmaz D., Murry C.E., Nochlin D., and Snow A.D. Detection and quantitation of perlecan mRNA levels in Alzheimer's disease and normal aged hippocampus by competitive reverse transcription-polymerase chain reaction. *Journal of Neurochemistry* 67:1132-1144, 1996.
36. Snow A.D. and Castillo G.M. Specific proteoglycans as potential causative agents and relevant targets for therapeutic intervention in Alzheimer's disease and other amyloidoses. *Amyloid: International Journal of Experimental and Clinical Investigation*. 4:135-141, 1997.
37. Miller J.D., Cummings J., Maresh G.A., Walker D.G., Castillo G.M., Ngo C., Kimata K., Kinsella M.G., Wight T.N., and Snow A.D. Localization of perlecan to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus. *Glia* 21:228-243, 1997.
38. Castillo G.M., Ngo C., Cummings J., Wight T.N. and Snow A.D. Perlecan binds to Alzheimer's disease beta-amyloid proteins (A β), accelerates A β fibrillogenesis and maintains A β fibril stability. *Journal of Neurochemistry* 69:2452-2465, 1997.

39. Castillo G.M., Cummings J., Yang Y., Judge M.E., Sheardown M.J., Rinvall K., Bondo-Hansen J. and Snow A.D. The sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. *Diabetes* 47:612-620, 1998.
40. Castillo G.M., Lukito W., Wight T.N., and Snow A.D. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. *Journal of Neurochemistry* 72:1681-1687, 1999.
41. Castillo G.M., Lukito W., Peskind E., Raskind M., Kirschner D.A., Yee A.G. and Snow A.D. Laminin inhibition of β -amyloid protein (A β) fibrillogenesis and identification of an A β binding site localized to the globular domain repeats on the laminin A chain. *Journal of Neuroscience Research* 62:451-462, 2000.
42. Hart M., Li L., Tokunaga T., Lindsey J.R., Hassell J.R., Snow A.D. and Fukuchi, K. Overproduction of perlecan core protein in cultured cells and transgenic mice. *Journal of Pathology* 194:262-269, 2001.
43. Kirschner D.A., Gross A.A.R., Hidalgo M. M., Inouye H., Gleason K.A., Abdelsayed G.A., Castillo G.M., Snow A.D., Pozo-Ramajo A., Petty S.A., and Decatur S.M. Fiber diffraction as a screen for amyloid inhibitors. *Current Alzheimer Res.* 5:288-307, 2008.